Literature DB >> 26415912

Mesenchymal Stem Cells and Cell Therapy for Bone Repair.

Shihua Wang, Pengchao Xu, Xiaoxia Li, Xiaodong Su, Yunfei Chen, Li Wan, Linyuan Fan, Kan Yin, Yan Liu, Robert Chunhua Zhao1.   

Abstract

Mesenchymal stem cells (MSCs) represent a new therapeutic paradigm for a number of diseases because they possess unique biological characteristics such as multipotency, immunomodulation and production of cytokines. Currently, 425 MSC based clinical trials have been conducted for at least 12 kinds of pathological conditions, with many completed trials demonstrating the safety and efficacy of MSCs. Here, we provide an overview of the clinical status of MSCs by searching the public clinical trials database http://clinicaltrials.gov. Particularly, the role of MSCs in clinical trials to treat bone defects and injuries is highlighted.

Entities:  

Mesh:

Year:  2016        PMID: 26415912     DOI: 10.2174/1874467208666150928153758

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  2 in total

1.  Human peripheral blood-derived mesenchymal stem cells with NTRK1 over-expression enhance repairing capability in a rat model of Parkinson's disease.

Authors:  Kun Liu; Wei Zhang; Yunlong Li; Qingfeng Ding; Yunan Bai; Fachen Wang; Guangming Xu
Journal:  Cytotechnology       Date:  2018-07-05       Impact factor: 2.058

Review 2.  Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.

Authors:  Raphael Gorodetsky; Wilhelm K Aicher
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.